Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Clinical and Cardiovascular Characteristics of Patients Suffering ST-Segment Elevation Myocardial Infarction After Covid-19: A Systematic Review and Meta-Analysis

Abdullah Gharibzadeha, Farzad Shahsanaeib, and Nima Rahimi Petru dic,∗

From the a Assistant Professor of Cardiology, Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran, b Interventional Cardiologist, Hypertension Research center, Cardiovascular Research Institute, Isfahan University Of Medical Sciences, Isfahan, Iran and c Resident Of Cardiology, Cardiovascular Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

Abstract: ST-segment elevation myocardial infarction (STEMI) is one of the fatal complications following Covid-19. We aimed to systematically assess the clinical sequels as well as cardiovascular findings in patients suffering STEMI following Covid-19. The manuscripts databases including PubMed, Web of knowledge (ISI), SCOPUS, Embase, and Google Scholar were deeply searched by the two reviewers using the relevant keywords related to the issue considered in the current review. Of 88 studies initially reviewed, 9 articles were included in final assessment. Nine articles including 447 patients with Covid-19 were included in the study. In terms of electrocardiographic findings, anterior lead involvement was reported in 12% - 61.6% of cases, inferior lead in 28.2% - 75% and lateral involvement in 7.7% - 100% of cases. The prevalence of LBBB was in the range of 10.7% - 61.6% of cases. In terms of echocardiographic...
findings, a decrease in left ventricular ejection fraction was reported in 60% - 88% of patients. Wall motion abnormality was also observed in 60% - 82.1% of patients. In terms of angiographic findings, the multivessel disease was reported in 17.9% - 69% of cases. Also, 24% - 83% of cases needed to revascularization procedures. Cardiac arrest was also reported in 3.1% - 28.2% of cases. Based on the meta-analysis performed on the mortality of patients with STEMI in the field of Covid-19, the pooled prevalence of mortality was estimated at 25.2% (95%CI:17.5%-34.8%). Mortality and adverse consequences of STEMI in patients with Covid-19 are far higher than in the general population. Therefore, in-hospital cardiovascular tracking and monitoring of Covid-19 patients with potential cardiovascular disorders is necessary to achieve a more favorable outcome. (Curr Probl Cardiol 2023;48:101045.)

Introduction

Evidence for the short- and long-term effects of the current Covid-19 pandemic indicates that the path of preventive and curative management of the disease requires fundamental changes and improvements to maximize patient survival and reduce disability to the maximum possible level. According to the latest figures from the World Health Organization, more than 205 million cases of Covid-19 have been reported, leading to more than 4 million deaths.1 In our country, Iran, according to the same report, the latest morbidity and mortality rates are estimated at 4.5 million cases and more than 100,000 cases, respectively.1 Significant in mortality as well as post-infection disabilities are the potential complications of virus invasion to the extent that there is a possibility of involvement of various vital organs due to direct invasion of the virus or indirect consequences of the resulting virus.2,3 In this regard, the occurrence of complications such as vascular thrombosis on the one hand and direct tissue invasion of the virus due to competition and high tendency to bind to tissue receptors (such as ACE II receptor) are the main factors in organic complications of the virus.4,5 In this regard, the likelihood of coronary artery atherosclerosis, endothelial dysfunction, thrombotic microangiopathy and activation of coagulopathic cascades, and ultimately increase the patient’s susceptibility to ischemic heart attack
and even ST-segment elevation myocardial infarction (STEMI) is expect-
able following severe Covid-19 disease. Several cases of STEMI have
been observed following Covid-19, which in many cases, invasive ther-
apeutic intervention such as PCI or CABG required. However, due to
the fear of hospitalization in a high epidemic situation and also the alloca-
tion of the majority of hospital wards to Covid-19 patients, in many cases
the above treatment interventions are associated with significant delays
and therefore morbidity and mortality due to delays in treatment should
also be added to the above statistics. Overall, summarizing the statist-
tics presented on the clinical consequences and cardiovascular outcomes
of the Covid-19 pandemic provides a clearer picture of the complications
of the disease. What we will discuss in the present study will be a system-
atic review of the clinical features as well as cardiovascular features of
patients with STEMI following Covid-19.

Materials and Methods

The main issues focused in our systematic review and meta-analysis
was to describe the clinical as well as electrocardiographic, echocardio-
graphic, and angiographic features of STEMI in patients suffering Covid-
19. The current systematic review followed the principles of the
“Preferred Reporting Items for Systematic Reviews and Meta-Analyses”
guideline. First, all manuscripts related to the pointed issue were
depth searched by the two reviewers using the related keywords includ-
ing “ST-segment elevation myocardial infarction”, “Covid-19”,
electrocardiography”, “echocardiography” and “angiography” in the
international manuscript databases such as PubMed, Web of knowledge
(ISI), SCOPUS, Embase, and Google Scholar. Any disagreement across
our reviewers was rechecked by the third reviewer as the final arbitrator.
The details of eligibility and the reasons for excluding the papers were
shown schematically (Fig 1). In the inclusion criteria for selecting the
articles were (1) English language papers, (2) The articles with complete
structure and contents, and (3) Access to the full text of the article. Thus,
the manuscripts with only abstract availability or with incomplete infor-
mation were not included in to our review. The retrieved articles were
placed in Endnote software and then duplicate and shared articles were
removed in the foreword databases. Finally, the obtained information
was categorized and analyzed by descriptive statistics and content analy-
sis. The study quality was evaluated based on the following criteria: (1)
the systematic review and meta-analysis based on the questions primarily
described and formulated; (2) predefined criteria for including and
88 potentially records identified through databases searching

3 duplicate removed

85 records screened

70 Excluded based on title/abstract review
2 full text unavailability
1 Non-English

12 full-texts articles assessed for eligibility

3 Excluded due to incomplete baseline data

9 included into meta-analysis

FIG 1. The flowchart of screening the eligible studies.
excluding the assessed studies as eligibility criteria; (3) searching the literature performed on a systematic and comprehensive approach; (4) to minimize the bias, the full texts of the article were dually reviewed; (5) the quality of included studies were rated independently by the reviewers for appraising internal validity; (6) studies’ characteristics and findings were comprehensively listed; (7) the publication and risk of bias were listed; and (8) heterogeneity was also assessed. The risk of bias for each study was assessed using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions and also according to QUADAS-2 tool. Of the 27 articles available, a total of 12 full-text articles were retrieved and placed at Endnote. After considering the inclusion and exclusion criteria and eliminating duplicate and common articles in the foreword databases, 9 articles were obtained and finally assessed. At this stage, all obtained articles were studied separately and the type of article and the main axis of the article were reviewed and extracted. For statistical analysis, the Comprehensive Meta-Analysis Software (CMA, version 3.0) was employed. We presented dichotomous data related to pooled prevalence of STEMI-related death following Covid-19 as prevalence rate and its 95% Confidence Interval (CI). Data were assessed by both fixed effects and random effect models, however the random effect analyses were reported if the heterogeneity was significant evaluated by the I2 statistic.

**Results**

In the present study, 88 studies were initially evaluated. With the removal of 3 duplicated articles, 85 articles were reviewed in the next stage, of which 70 were excluded from the study based on the titles of the articles and a review of their abstracts, 2 articles due to lack of access to the full text of the article and 1 article due to the non-English language, and a total of 12 studies were included in the content evaluation in the next stage. At this stage, 3 articles were excluded from the study due to insufficient information and variables required to perform the project, and finally 9 articles were included in the final review and analysis (Fig 1).13-21 According to the criteria of QUADAS-2 scoring system in which articles are examined based on features such as patient selection, study index test, evaluation of outcome and validity of results and findings, and writing of article texts, none of the articles was classified at a low level and therefore all 9 articles were included in the systematic review (Fig 2).

As summarized in Table 1, in total, 9 articles including 447 patients with Covid-19 were included in the study. Of these, 336 were male and
111 were female. The age of patients ranged from 56 to 68 years. With the exception of one study that reported the results of its one-month follow-up, the results of other studies focused on in-hospital findings. Also, 3 of the 9 studies were conducted in a multi-center manner. In terms of cardiovascular characteristics and findings in the studied patients, the following results were obtained (Table 2): (1) In terms of electrocardiographic findings, anterior lead involvement was reported in 12% – 61.6% of cases, inferior lead in 28.2 to 75% and lateral involvement in 7.7% - 100% of cases. The prevalence of LBBB was in the range of 10.7% - 61.6% of cases. Another finding on the ECG included left axis deviation, which was visible in 50% of patients. (2) In terms of echocardiographic findings, firstly, a decrease in left ventricular ejection fraction or LVEF (to less than 35%) was reported in 60% - 88% of patients. Wall motion abnormality was also observed in 60% - 82.1% of patients. (3) In terms of angiographic findings, first, the occurrence of multi-vessel disease was reported in 17.9% - 69% of cases. Also, 24% - 83% of cases needed to revascularization procedures. Cardiac arrest was also reported in 3.1% - 28.2% of cases. (4) In terms of other clinical outcomes, cardiogenic shock was reported in 18.5% of cases, need for intubation in 12.8% - 42% of cases, recurrent myocardial infarction in 21% of cases, cerebral ischemia in 16% of cases and need for mechanical ventilation in 18%.

![FIG 2. Methodological quality of the included studies. (Color version of figure is available online.)](image-url)
### TABLE 1. The details of studies

| Author, country        | Study type                | Covid-19 Population (n) | Male/Female | Mean age | Follow-up time | Rate of STEMI |
|------------------------|---------------------------|-------------------------|-------------|-----------|----------------|---------------|
| Abizaid, Brazil¹³      | Multicenter prospective   | 152                     | 103/49      | 64.0      | In-hospital    | 83 (54.6%)    |
| Bakhshi, USA¹⁴         | Retrospective cohort      | 5                       | 5/0         | 56.8      | 1 month        | 3 (60.0%)     |
| Bangalore, USA¹⁵       | Retrospective cohort      | 18                      | 15/3        | 64.0      | In-hospital    | 8 (44.4%)     |
| Choudry, UK¹⁶          | Retrospective cohort      | 39                      | 33/6        | 61.7      | In-hospital    | 24 (61.5%)    |
| Hamadeh, USA¹⁷         | Multicenter retrospective | 78                      | 49/29       | 65.0      | In-hospital    | 78 (100%)     |
| Kaur, USA¹⁸            | Retrospective cohort      | 4                       | 4/0         | 60.2      | In-hospital    | 4 (100%)      |
| Rodriguez, Spain¹⁹     | Retrospective cohort      | 1010                    | 78/13       | 60.0      | In-hospital    | 91 (9.0%)     |
| Solano-Lopez, Spain²⁰  | Multicenter prospective   | 32                      | 29/3        | 66.0      | In-hospital    | 32 (100%)     |
| Stefanini, Italy²¹     | Retrospective cohort      | 28                      | 20/8        | 68.0      | In-hospital    | 25 (89.3%)    |
Based on the meta-analysis performed on the mortality of patients with STEMI in the field of Covid-19, the pooled prevalence of mortality was estimated at 25.2% (95% confidence interval of 17.5% - 34.8%) (Table 3). However, in terms of mortality reporting, the articles had significant

**TABLE 2. The details of cardiac involvement in COVID-19 patients**

| Author, country, country | Covid-19-related MI | Findings                                                                 | Mortality |
|--------------------------|--------------------|--------------------------------------------------------------------------|-----------|
| Abizaid, Brazil          | 83                 | Syntax score of 16, multi-vessel disease = 69%, complex lesion = 73%, thrombus containing lesion = 51.3% | 23.7% 19  |
| Bakhshi, USA             | 3                  | Low LVEF (<35%) = 60.0%, Wall motion abnormality = 60.0%,                | 40.0% 2   |
| Bangalore, USA           | 8                  | Anterior ST elevation = 12%, inferior ST elevation = 50%, Lateral change = 100%, Low ejection fraction = 88%, wall-motion abnormality = 75%, coronary artery disease = 100%, Percutaneous coronary intervention = 83% | 50.0% 4   |
| Choudry, UK              | 39                 | Anterior/LBBB = 61.6%, Inferior = 28.2%, Lateral = 7.7%, Cardiac arrest = 28.2%, Cardiogenic shock = 18.5%, Intubation = 12.8%, Coronary intervention = 97.4%, Multivessel thrombosis = 17.9% | 17.9% 7   |
| Hamadeh, USA             | 78                 | Coronary intervention = 24%, cardiac resuscitation=17%, Intubation = 42%, mechanical ventilation = 18%, re-infarction = 21%, ischemic stroke=16% | 12.0% 9   |
| Kaur, USA                | 4                  | Normal sinus rhythm = 100%, Left axis deviation = 50%, inferolateral = 75%, anterolateral = 25%, | 75.0% 3   |
| Rodriguez, Spain         | 91                 | Heart failure = 31.9%, mechanical thrombectomy=44%,                     | 23.1% 21  |
| Solano-Lopez, Spain      | 32                 | Cardiac arrest = 3.1%, ST-depression = 21.9%, ST-elevation = 62.5%, Multi-vessel coronary vessel = 51.6%, wall-motion abnormality = 82.1%, diffuse hypokinesia = 10.7%, reduced LVEF = 60%, culprit lesion requiring revascularization = 60.7%, coronary artery disease=39.3%, ST-depression = 21.9%, ST-elevation = 89.3%, LBBB = 10.7%, Reduced LVEF = 25%, wall-motion abnormality = 92.8% | 15.6% 5   |
| Stefanini, Italy         | 28                 |                                                                          | 39.3% 11  |
heterogeneity ($I^2$ index = 60.592, $P = 0.009$) (Fig 3). However, publication bias was not significant for the studied studies ($P$ value was 0.531) (Fig 4).

**Discussion**

Cardiovascular complications are among the most important and potentially fatal complications in patients with severe Covid-19. In general, regarding the effect of Covid-19 disease and coronavirus-related disease on the cardiovascular system, various mechanisms have been described, including the following: (1) Direct effect on myocardial tissue following direct invasion of virus, (2) Transmission of the virus through specific ACEII receptors located on myocardial tissue, (3) Increased susceptibility to vascular thrombosis, especially in coronary arteries, and

### TABLE 3. The details of calculating mortality related to STEMI following COVID-19

| Author, country       | Death rate | 95% Confidence Interval for death | $P$ value |
|-----------------------|------------|-----------------------------------|-----------|
| Abizaid, Brazil       | 22.9       | 15.1 - 33.1                       | 0.001     |
| Bakhshi, USA          | 66.7       | 15.4 - 95.7                       | 0.571     |
| Bangalore, USA        | 50.0       | 20.0 - 80.0                       | 1.000     |
| Choudry, UK           | 17.9       | 8.8 - 33.1                        | 0.001     |
| Hamadeh, USA          | 11.5       | 6.1 - 20.7                        | 0.001     |
| Kaur, USA             | 75.0       | 23.8 - 96.6                       | 0.341     |
| Rodriguez, Spain      | 23.1       | 15.6 - 32.8                       | 0.001     |
| Solano-Lopez, Spain   | 15.6       | 6.7 - 32.5                        | 0.001     |
| Stefanini, Italy      | 39.3       | 23.2 - 58.0                       | 0.261     |

![FIG 3. Pooled death rate related to STEMI following COVID-19 (death rate = 25.2%, 95% CI: 17.5% - 34.8%)](image)
FIG 4. Insignificant publication bias as evidenced by funnel plot asymmetry ($P = 0.531$).
increased risk of Cardiac ischemic disease, (4) Activation of inflammatory processes and thus production and secretion of inflammatory cytokines. The activation of the above processes will lead to a variety of cardiovascular disorders such as coronary heart disease, a variety of cardiac arrhythmias, acute heart failure, cardiomyopathies and eventually death due to the progression and exacerbation of heart disorders. One of the most important of these complications is acute myocardial infarction, especially STEMI due to Covid-19, which is considered as one of the fatal complications of this disease. What we focused on in the present systematic review was the assessment of the occurrence of STEMI in patients with Covid-19 as well as the associated cardiovascular findings. In this study, a total of 9 studies evaluating the occurrence of STEMI following Covid-19 were systematically reviewed and meta-analyzed. Thus, our primary target population was patients with coronary artery disease without evidence of cardiovascular involvement who had experienced STEMI during hospitalization or within 30 days of discharge.

What was considered an initial and important conclusion was that the clinical consequences of ischemic heart disease following Covid-19 disease appear to be far worse and the extent of the involvement far more severe than in cases without Covid-19. However, no comparative study has been conducted in this regard. In other words, a review of our findings shows that, first, the occurrence of STEMI in the context of Covid-19 is associated with a significant mortality of about 25.2%, and in fact about a quarter of patients with STEMI following Covid-19 seems to be non-survived. However, even in the case of one-year mortality of patients with MI in the general non-Covid-19 population, this number is lower than the rate reported in patients with Covid-19.22,23 In fact, Covid-19 infection appears to be an independent factor associated with an increased mortality rate in patients with STEMI. This is due to the fact that the cardiovascular involvement caused by Covid-19 will be much more severe than the general population with STEMI.

What we showed was the high prevalence of heart involvement in these patients based on electrocardiographic, echocardiographic, and angiographic findings. In this regard, it was shown that a significant reduction in LVEF was observed in 60% - 88% and wall motion abnormality in 60% - 82.1% of patients. Also, the occurrence of multi-vessel disease was reported in 17.9% - 69% of cases that 24% - 83% needed to schedule for coronary revascularization. Cases leading to cardiac arrest were also reported to be 3.1% - 28.2%. Also, re-infarction was reported in 21% of patients, all of which are significant. Accordingly, it should be acknowledged that given the far worse consequences of STEMI in
patients with Covid-19, it would be crucial to consider some precautions as soon as coronary heart disease is diagnosed, especially in patients with risk factors for heart disease: First, in the presence of cardiovascular risk factors, the program to control these risk factors should be a priority. Second, a comprehensive cardiovascular evaluation and monitoring of these patients during hospitalization is strongly recommended.

**Conclusion**

In conclusion, the severity and extent of STEMI following Covid-19 will be far greater than the general population without Covid-19. In this way, the rate of in-hospital mortality due to STEMI is also significant in these patients and according to the literature review, about a quarter of patients die within hospitalization. Therefore, control of cardiovascular risk factors as soon as possible in patients with Covid-19 will be critical as soon as they are admitted to the hospital with continuous monitoring.

**REFERENCES**

1. WHO Situation report 38: coronavirus disease (COVID-19), 2020. Available: https://www.who.int/publications/m/item/situation-report—38. February 27, 2020.
2. Medicine C for EB COVID 19: admissions to hospital, 2020. Available: https://www.cebm.net/covid-19/covid-19-uk-hospital-admissions/. May 1, 2020.
3. Mahmud E, Dauerman HL, Welt FGP, et al. Management of acute myocardial infarction during the COVID-19 pandemic: a consensus statement from the Society for cardiovascular angiography and interventions (ScaI), the American College of cardiology (ACC), and the American College of emergency physicians (ACEP). *Catheter Cardiovasc Interv* 2020;96:336–45. https://doi.org/10.1002/ccd.28946. [PubMed] [Google Scholar].
4. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J* 2018;39:119–77. https://doi.org/10.1093/eurheartj/ehx393. [PubMed] [Google Scholar].
5. Stefanini GG, Montorfano M, Trabattoni D, et al. St-Elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes. *Circulation* 2020;141:1–7. https://doi.org/10.1161/CIRCULATIONAHA.120.047525. [PMC free article] [PubMed] [Google Scholar].
6. Choudry FA, Hamshere SM, Rathod KS, et al. High Thrombus Burden in Patients With COVID-19 Presenting With ST-Segment Elevation Myocardial Infarction. *J Am Coll Cardiol* 2020;76:1168–76. https://doi.org/10.1016/j.jacc.2020.07.022. [PMC free article] [PubMed] [Google Scholar].
7. Inciardi RM, Adamo M, Lupi L, et al. Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in northern Italy. *Eur Heart J*
8. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. *Blood* 2020;135:2033–40. https://doi.org/10.1182/blood.2020006000. [PMC free article] [PubMed] [Google Scholar].

9. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *The Lancet* 2020;395:1417–8. https://doi.org/10.1016/S0140-6736(20)30937-5. [PMC free article] [PubMed] [Google Scholar].

10. Lopes da Silva R. Viral-Associated thrombotic microangiopathies. *Hematol Oncol Stem Cell Ther* 2011;4:51–9. https://doi.org/10.5144/1658-3876.2011.51. [PubMed] [Google Scholar].

11. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intensive Care Med* 2020;46:1089–98. https://doi.org/10.1007/s00134-020-06062-x. [PMC free article] [PubMed] [Google Scholar].

12. Moher D, Shamseer L, Clarke M. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4(1):1. https://doi.org/10.1186/2046-4053-4-1.

13. Abizaid Alexandre, 1 2 3, Campos Carlos M, 1 4, Guimarães Patrícia O, 1, et al. Patients with COVID-19 who experience a myocardial infarction have complex coronary morphology and high in-hospital mortality: Primary results of a nationwide angiographic study. *Catheter Cardiovasc Interv* 2021 Sep;98(3):E370–8. https://doi.org/10.1002/ccd.29709. Epub 2021 Apr 27.

14. Bakhshi Hooman, 1, Donti Nisha, 1, Ekanem Emmanuel, 1. The clinical spectrum of myocardial injury associated with COVID-19 infection. *J Community Hosp Intern Med Perspect* 2020 Oct 29;10(6):521–2. https://doi.org/10.1080/20009666.2020.1809910.

15. Bangalore Sripal, 1, Sharma Atul, 1, Slotwiner Alexander, 1. ST-segment elevation in patients with Covid-19 - A case series. *N Engl J Med* 2020;382(25):2478–80. https://doi.org/10.1056/NEJMc2009020. Epub 2020 Apr 17.

16. Choudry Fizzah A, 1, Hamshere Stephen M, 1, Rathod Krishnaraj S, 1, et al. High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2020;76(10):1168–76. https://doi.org/10.1016/j.jacc.2020.07.022. Epub 2020 Jul 14.

17. Hamadeh Anas, 1, Aldujeli Ali, 2, Briëdis Kasparas, 2. Characteristics and Outcomes in Patients Presenting With COVID-19 and ST-Segment Elevation Myocardial Infarction. *Am J Cardiol* 2020;131:1–6. https://doi.org/10.1016/j.amjcard.2020.06.063. Epub 2020 Jul 3.

18. Kaur Parminder, 1, Patel Prem, 2, Singh Balraj, 2. ST-Segment Elevation in Patients with COVID-19: A Late Complication. *Am J Med Sci* 2021;361(3):403–5. https://doi.org/10.1016/j.amjms.2020.09.019. Epub 2020 Oct 2.

19. Rodríguez-Leor Oriol, 1, Cid Alvarez Ana Belen, Pérez de Prado Armando. In-hospital outcomes of COVID-19 ST-elevation myocardial infarction patients. *EuroIntervention* 2021;16(17):1426–33. https://doi.org/10.4244/EIJ-D-20-00935.10.1161/CIRCULATIONAHA.120.047525. Epub 2020 Apr 30.
20. Solano-López J, Zamorano JL, A Pardo Sanz, et al. Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak. *Rev Esp Cardiol (Engl Ed)* 2020;73(12):985–93. https://doi.org/10.1016/j.rec.2020.07.009. Epub 2020 Jul 31.

21. Stefanini Giulio G, 1, Montorfano Matteo, 2, Trabattoni Daniela, 3. ST-elevation myocardial infarction in patients With COVID-19: clinical and angiographic outcomes. *Circulation* 2020;141(25):2113–6.

22. Ali M, 1 2, Lange SA, 3 4, Wittlinger T, 3, Lehnert G, 3, Rigopoulos AG, 5, Noutsias M, 5. In-hospital mortality after acute STEMI in patients undergoing primary PCI. *Herz* 2018;43(8):741–5. https://doi.org/10.1007/s00059-017-4621-y. Epub 2017 Oct 9.

23. Rodríguez-Padial Luis, 1, Fernández-Pérez Cristina, 2, Bernal José L, 3. Differences in in-hospital mortality after STEMI versus NSTEMI by sex. Eleven-year trend in the Spanish National Health Service. *Rev Esp Cardiol (Engl Ed)* 2021;74(6):510–7. https://doi.org/10.1016/j.rec.2020.04.017. Epub 2020 Jun 16.